



Title Multicenter, Randomized, Sham-controlled, Investigator- and Owner- masked pivotal safety and efficacy study of intratumoral EBC-46 to treat canine cutaneous and subcutaneous mast cell tumors.

Purpose Canine mast cell tumors are a type of malignant cancer that are difficult to treat effectively. In this study, researchers will test the benefit of a novel and natural product given by injection into the mast cell tumor. Study patients will be randomized to either receive this product or a control treatment.

Eligibility To be eligible for this study, dogs must meet several criteria, including but not limited to the following:

- Clinically confirmed diagnosis of cutaneous or subcutaneous mast cell tumor.
- Must be able to bring your dog into the clinic for regularly scheduled recheck visits.

For more information about this study and to inquire about eligibility and potential study benefits, please contact Nicole Leibman, DVM, DACVIM (Oncology) 212-329-8696 or 212-329-8740 (nicole.leibman@amcny.org).